GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy

Law360, Washington (August 16, 2012, 1:35 PM EDT) -- GlaxoSmithKline LLC and Teva Pharmaceuticals USA Inc. urged a New Jersey federal judge on Wednesday to dismiss a putative class action that accuses them of conspiring to keep a generic epilepsy drug off the market, saying the licensing agreement relating to GSK's patent exclusivity is protected by law from antitrust litigation.

GSK and Teva reached a patent dispute settlement in 2005 that allowed the generic-drug maker to sell versions of GSK's Lamictal before the company lost exclusivity rights to the epilepsy treatment, but drug distributors Louisiana...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.